Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 3, 2008, Pages 216-225

  Akatsuka, Toshio ^a,c   Mochizuki, Toshio ^b   Koike, Takao ^b  

^a Akatsuka Clinic   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c Akatsuka Clinic   (Japan)

Author keywords

Acidosis; Chronic dialysis; Hyperparathyroidism; Phosphate binder; Sevelamer hydrochloride

Indexed keywords

CALCIUM CARBONATE; CHLORIDE; SEVELAMER; VITAMIN D;

ABDOMINAL DISTENSION; ACID BASE BALANCE; AGED; ARTICLE; CHLORIDE BLOOD LEVEL; CLINICAL ARTICLE; CONSTIPATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; MALE; METABOLIC ACIDOSIS; MONOTHERAPY; PRIORITY JOURNAL;

ACIDOSIS; AGED; BUFFERS; CALCIUM CARBONATE; CHELATING AGENTS; FEMALE; HUMANS; MALE; POLYAMINES; RENAL DIALYSIS;

EID: 44349141091     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00577.x     Document Type: Article

References (21)

1. Goldberg DI, Dillon MA, Slatopolsky EA et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998 13 : 2303 10.
2. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999 33 : 694 701.
3. National Kidney Foundation. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 : S1 S201.
4. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973 4 : 643 6.
5. Stewart PA. Modern quantitative acid-base chemistry. Can J Physiol Pharmacol 1983 61 : 1444 61.
6. Figge J, Rossing TH, Fencl V. The role of serum proteins in acid-base equilibria. J Lab Clin Med 1991 117 : 453 67.
7. Figge J, Mydosh T, Fencl V. Serum proteins and acid-base equilibria: a follow-up. J Lab Clin Med 1992 120 : 713 19.
8. Shapiro BA, Peruzzi WT. Interpretation of blood gases. In : Shoemaker WC, Ayres SM, Grenik A, Holbrook P, eds. Textbook of Critical Care, 3rd edn. Philadelphia : WB Saunders Company, 1995 274 90.
9. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992 19 : 303 17.
10. Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991 6 : 170 5.
11. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in hemodialysis patients. Nephrol Dial Transplant 2004 19 : 1489 96.
12. Goodman WG, London G, Amann K et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004 43 : 572 9.
13. Slatopolsky E, Gonzalez E, Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003 21 : 318 26.
14. Chertow GM. Slowing the progression of vascular calcification in hemodialysis. J Am Soc Nephrol 2003 14 : S310 S314.
15. Burke SK. Arterial calcification in chronic kidney disease. Semin Nephrol 2004 24 : 403 7.
16. Chertow GM, Burke SK, Lazarus JM et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997 29 : 66 71.
17. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int 2000 57 : 1776 7.
18. Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernandez E. Treatment with Sevelamer Decreases Bicarbonate Levels in Hemodialysis Patients. (Letter to the editor). Nephron 2002 92 : 499 500.
19. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int Suppl 2004 66 : S39 S45.
20. Chertow GM, Dillon MA, Burke SK et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Clin Nephrology 1999 51 : 18 26.
21. Borras M, Marco MP, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit Dial Int 2002 22 : 737 8.